MOESM6 of In-feed bambermycin medication induces anti-inflammatory effects and prevents parietal cell loss without influencing Helicobacter suis colonization in the stomach of mice

Additional file 6. Overview of the relative fold changes of altered markers for gastric acid secretion in the bambermycin-supplemented and non-supplemented groups. The data are presented as fold changes in gene expression normalized to 3 reference genes and relative to control groups 1 and 4 (i.e. group 2-4 relative to group 1 and group 5-6 relative to group 4) which are considered as 1. The fold changes are shown as means with the standard error of the mean. Statistical differences were calculated using the non-parametric Kruskal–Wallis H test SPSS statistics 24®. A P-value lower than 0.05 is considered to be significant. Group 2 = 32 ppm bambermycin supplemented, non-H. suis infected group; group 3 = 64 ppm bambermycin supplemented, non-H. suis infected group; group 4 = H. suis-positive control group without bambermycin supplementation; group 5 = 32 ppm bambermycin supplemented, H. suis infected group; group 6 = 64 ppm bambermycin supplemented, H. suis infected group

MOESM8 of In-feed bambermycin medication induces anti-inflammatory effects and prevents parietal cell loss without influencing Helicobacter suis colonization in the stomach of mice

Additional file 8. Bacterial community compositions present in the stomach of each individual mice. The cumulated histograms show the relative abundance of the identified taxa at phylum (A), family (B) or genus (C) level. At family and genus level, taxa with a relative abundance < 1% are merged in the category “others”. M1_ = group 1 = H. suis-negative control group without bambermycin supplementation; M2_ = group 2 = 32 ppm bambermycin supplemented, non-H. suis infected group; M3_ = group 3 = 64 ppm bambermycin supplemented, non-H. suis infected group; M4_ = group 4 = H. suis-positive control group without bambermycin supplementation; M5_ = group 5 = 32 ppm bambermycin supplemented, H. suis infected group; M6_ = group 6 = 64 ppm bambermycin supplemented, H. suis infected group. The unclassified populations correspond to defined groups of the genus level for which a taxonomical classification assignation to the genus cannot be attributed. These populations are therefore labelled with the first defined superior hierarchical taxonomic level followed by “_unclassified” to prevent confusion

MOESM7 of In-feed bambermycin medication induces anti-inflammatory effects and prevents parietal cell loss without influencing Helicobacter suis colonization in the stomach of mice

Additional file 7. Overview of the number of pyrosequencing reads for each mice. Group 1 = H. suis-negative control group without bambermycin supplementation; group 2 = 32 ppm bambermycin supplemented, non-H. suis infected group; group 3 = 64 ppm bambermycin supplemented, non-H. suis infected group; group 4 = H. suis-positive control group without bambermycin supplementation; group 5 = 32 ppm bambermycin supplemented, H. suis infected group; group 6 = 64 ppm bambermycin supplemented, H. suis infected group

MOESM10 of In-feed bambermycin medication induces anti-inflammatory effects and prevents parietal cell loss without influencing Helicobacter suis colonization in the stomach of mice

Additional file 10. An overview of the main differences in relative abundance of taxa at phylum, family, genus and species level in the bambermycin-supplemented and non-supplemented groups. The data are presented as the mean relative abundance of the taxa with the standard error of the mean. Statistical differences were calculated using the non-parametric Kruskal–Wallis tests with Tukey post hoc tests and Benjamini–Hochberg False Discovery Rate were performed using STAMP®. A P-value lower than 0.05 is considered to be significant